纤维蛋白胶顺铂凝胶化疗的缓释特性  

Sustained dynamic release characteristics of fibrin glue enwrapping cisplatin

作　　者：徐向东[1] 卢向红[1] 施勇[1] 叶冠雄[1] 朱锡元[1] 

机构地区：[1]浙江省丽水市人民医院,浙江323000

出　　处：《中华医学杂志》2011年第18期1246-1249,共4页National Medical Journal of China

基　　金：浙江省科技计划项目（2006C33015）

摘　　要：目的探讨纤维蛋白胶顺铂凝胶化疗的缓释特性。方法体内释放实验中，将顺铂和纤维蛋白胶混合成凝胶20例为实验组，单纯顺铂化疗20例为对照组，定时取少量外周血和尿液作样本，测试样本中顺铂浓度，计算外周血及尿液中顺铂的动力学参数。结果体内实验显示，外周血顺铂峰浓度实验组和对照组分别为（192．2±33．5）μg／L、（1077．6±176．6）μg／L，实验组显著低于对照组（P〈0．01）；尿液顺铂峰浓度实验组和对照组分别为（18．6±8．7）μg／L、（55．8±12．7）μg／L，实验组显著低于对照组（P〈0．01），外周血实验组的消除半衰期为23．32h，而对照组为13．93h，外周血及尿液中的顺铂消除半衰期及曲线下面积实验组均明显长于或大于对照组（P〈0．01）。结论在体内条件下纤维蛋白胶顺铂凝胶具有良好的缓释性，在腹腔局部使用，可延长顺铂在腹腔的滞留时间，降低外周血的铂类浓度。Objective To summarize the sustained dynamic release characteristics of fibrin glue enwrapping cisplatin. Methods In this in vivo study, 20 patients received fibrin glue enwrapping cisplatin placed into the abdominal cavity while another 20 patients received cisplatin as the control group. Their peripheral blood and urine samples were collected at a regular interval to determine the concentrations and the pharmacokinetic parameters of cisplatin. Results The peak peripheral blood concentration of cisplatin in the study group was significantly lower than that in the control group [ （ 192. 2 ± 33.5 ） vs （ 1077.6± 176.6） μg/L, P 〈 0. 01 ]. And the peak urine concentration of cisplatin was significantly lower in the study group than that in the control group [ （ 18.6±8.7） vs （55.8± 12.7） μg/L, P 〈 0. 01 ]. The elimination half-life of cisplatin was 23.32 h and 13.93 h respectively in the study and control groups. The elimination half-life and the area under the curve in peripheral blood and urine samples of the study group were significantly longer than those of the control group （P 〈 0. 01 ）. Conclusion The fibrin glue enwrapping cisplatin has the excellent in vivo characteristics of sustained dynamic release. Thus it may prolong the retention of cisplatin in abdominal cavity and lower its concentration in peripheral blood.

关 键 词：纤维蛋白组织粘着剂 顺铂 迟效制剂 药代动力学 

分 类 号：R735.2[医药卫生—肿瘤]